Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid drug therapy in high-unmet need neuropathic pain...

Related Keywords

Texas ,United States ,Bristol Myers Squibb ,Lisa Defrancesco ,Alina Cocuzza ,Craig Granowitz ,Globenewswire Inc ,Lexicon Pharmaceuticals ,Exchange Commission ,Nasdaq ,Drug Administration ,Lexicon Pharmaceuticals Inc ,Fast Track ,Multicenter Study ,Open Label Extension ,Diabetic Peripheral Neuropathic Pain ,Average Daily Pain Score ,Myers Squibb ,Investor Inquiries ,Media Inquiries ,Markets ,